Effects of a Diabetes Prevention Program on Type 2 Diabetes Risk Factors and Quality of Life Among Latino Youths With Prediabetes: A Randomized Clinical Trial.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
01 09 2022
Historique:
entrez: 12 9 2022
pubmed: 13 9 2022
medline: 15 9 2022
Statut: epublish

Résumé

Latino youths are disproportionately impacted by prediabetes and type 2 diabetes (T2D). Lifestyle intervention is the first-line approach for preventing or delaying T2D among adults with prediabetes. To assess the efficacy of a diabetes prevention program among Latino youths aged 12 to 16 years with prediabetes. This 2-group parallel randomized clinical trial with 2:1 randomization assessed a lifestyle intervention against usual care among Latino youths with prediabetes and obesity with 6- and 12-month follow-up. The study was conducted at YMCA facilities in Phoenix, Arizona from May 2016 to March 2020. Participants were randomized to lifestyle intervention (INT) or usual care control (UCC). The 6-month INT included 1 d/wk of nutrition and health education and 3 d/wk of physical activity. UCC included 2 visits with a pediatric endocrinologist and a bilingual, bicultural registered dietitian to discuss diabetes risks and healthy lifestyle changes. Insulin sensitivity, glucose tolerance, and weight-specific quality of life (YQOL-W) at 6- and 12-month follow-up. A total of 117 Latino youths (mean [SD] age, 14 [1] years; 47 [40.1%] girls) were included in the analysis. Overall, 79 were randomized to INT and 38 to UCC. At 6 months, the INT led to significant decreases in mean (SE) 2-hour glucose (baseline: 144 [3] mg/dL; 6 months: 132 [3] mg/dL; P = .002) and increases in mean (SE) insulin sensitivity (baseline: 1.9 [0.2]; 6 months: 2.6 [0.3]; P = .001) and YQOL-W (baseline: 75 [2]; 6 months: 80 [2]; P = .006), but these changes were not significantly different from UCC (2-hour glucose: mean difference, -7.2 mg/dL; 95% CI, -19.7 to 5.3 mg/dL; P for interaction = .26; insulin sensitivity: mean difference, 0.1; 95% CI, -0.7 to 0.9; P for interaction = .79; YQOL-W: mean difference, 6.3; 95% CI, -1.1 to 13.7; P for interaction = .10, respectively). Both INT (mean [SE], -15 mg/dL [4.9]; P = .002) and UCC (mean [SE], -15 mg/dL [5.4]; P = .005) had significant 12-month reductions in 2-hour glucose that did not differ significantly from each other (mean difference, -0.3; 95% CI, -14.5 to 14.1 mg/dL; P for interaction = .97). At 12 months, changes in mean (SE) insulin sensitivity in INT (baseline: 1.9 [0.2]; 12 months: 2.3 [0.2]; P = .06) and UCC (baseline: 1.9 [0.3]; 12 months: 2.0 [0.2]; P = .70) were not significantly different (mean difference, 0.3; 95% CI, -0.4 to 1.0; P for interaction = .37). At 12 months, YQOL-W was significantly increased in INT (basline: 75 [2]; 12 months: 82 [2]; P < .001) vs UCC (mean difference, 8.5; 95% CI, 0.8 to 16.2; P for interaction = .03). In this randomized clinical trial, both INT and UCC led to similar changes in T2D risk factors among Latino youths with diabetes; however, YQOL-W was improved in INT compared with UCC. Diabetes prevention interventions that are effective in adults also appeared to be effective in high risk youths. ClinicalTrials.gov Identifier: NCT02615353.

Identifiants

pubmed: 36094502
pii: 2795971
doi: 10.1001/jamanetworkopen.2022.31196
pmc: PMC9468887
doi:

Substances chimiques

Glucose IY9XDZ35W2

Banques de données

ClinicalTrials.gov
['NCT02615353']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2231196

Subventions

Organisme : NIMHD NIH HHS
ID : P20 MD002316
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK134978
Pays : United States
Organisme : NIMHD NIH HHS
ID : L60 MD003594
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK127015
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK107579
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Diabetes Care Educ Newsl. 2012 Summer;33(4):4-7
pubmed: 26451082
JAMA. 2019 Dec 24;322(24):2389-2398
pubmed: 31860047
Diabetes Care. 2019 Jan;42(Suppl 1):S148-S164
pubmed: 30559239
Pediatr Diabetes. 2010 Sep;11(6):417-23
pubmed: 19912553
J R Soc Med. 2011 Dec;104(12):510-20
pubmed: 22179294
J Pediatr. 2012 Jun;160(6):911-7
pubmed: 22217471
Diabetes Educ. 2013 Jan-Feb;39(1):109-18
pubmed: 23150531
J Clin Endocrinol Metab. 2004 Mar;89(3):1096-101
pubmed: 15001593
Exerc Sport Sci Rev. 2015 Jan;43(1):41-7
pubmed: 25390295
N Engl J Med. 1988 Dec 8;319(23):1500-6
pubmed: 3054559
J Pediatr. 2012 Jul;161(1):51-7
pubmed: 22325254
Obesity (Silver Spring). 2007 Nov;15(11):2553-6
pubmed: 18070745
JAMA Pediatr. 2020 Feb 1;174(2):e194498
pubmed: 31790544
Diabetes Care. 2005 Apr;28(4):902-9
pubmed: 15793193
Annu Rev Psychol. 2009;60:549-76
pubmed: 18652544
JAMA. 2021 Aug 24;326(8):717-727
pubmed: 34427600
Diabetes Care. 2009 Jan;32(1):45-7
pubmed: 18840769
Qual Life Res. 2011 Aug;20(6):961-8
pubmed: 21188537
Diabetes Care. 2021 Nov;44(11):2457-2459
pubmed: 34670795
Diabetes Care. 2014 Feb;37(2):317-24
pubmed: 24062325
Prev Med Rep. 2019 Mar 04;14:100840
pubmed: 30911460
Diabetes. 1980 Jan;29(1):41-9
pubmed: 7380107
Int J Surg. 2011;9(8):672-7
pubmed: 22019563
JAMA. 2019 Nov 5;322(17):1707-1708
pubmed: 31566652
JAMA. 2003 Oct 8;290(14):1884-90
pubmed: 14532317
Trials. 2020 Aug 14;21(1):716
pubmed: 32799920
Implement Sci. 2015 Dec 15;10:172
pubmed: 26670418
Milbank Q. 2020 Mar;98(1):172-196
pubmed: 31994260
J Clin Endocrinol Metab. 2008 Nov;93(11):4231-7
pubmed: 18713820
Curr Diab Rep. 2020 Aug 28;20(10):51
pubmed: 32857299
Diabetes. 2012 Mar;61(3):606-14
pubmed: 22315322
Diabetes. 2005 Aug;54(8):2404-14
pubmed: 16046308
Qual Life Res. 2011 Mar;20(2):215-24
pubmed: 20820926
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Nat Rev Endocrinol. 2013 Oct;9(10):607-14
pubmed: 23897171
Diabetes Care. 2021 Dec;44(12):2691-2698
pubmed: 34607833
MMWR Suppl. 2016 Jul 08;65(3):1-3
pubmed: 27389046
J Clin Endocrinol Metab. 2020 Feb 1;105(2):
pubmed: 31972003
J Behav Med. 2009 Feb;32(1):89-105
pubmed: 19101788
BMJ Clin Evid. 2011 Apr 04;2011:
pubmed: 21463538
N Engl J Med. 2001 May 3;344(18):1343-50
pubmed: 11333990
BMC Public Health. 2017 Mar 16;17(1):261
pubmed: 28302101
Res Q Exerc Sport. 2004 Sep;75(3):259-71
pubmed: 15487290
Diabetes Educ. 2012 Jul-Aug;38(4):504-12
pubmed: 22585870
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
J Pediatr. 2020 Apr;219:11-22
pubmed: 32143933
Depress Anxiety. 2017 Oct;34(10):866-876
pubmed: 28370947
Obesity (Silver Spring). 2018 Dec;26(12):1856-1865
pubmed: 30426694
Curr Probl Pediatr Adolesc Health Care. 2019 Jan;49(1):16-22
pubmed: 30567629
Contemp Clin Trials. 2018 Dec;75:19-28
pubmed: 30342256
Front Public Health. 2013 Aug 23;1:29
pubmed: 24350198

Auteurs

Armando Peña (A)

Center for Health Promotion and Disease Prevention, Arizona State University, Phoenix.

Micah L Olson (ML)

Center for Health Promotion and Disease Prevention, Arizona State University, Phoenix.
Division of Pediatric Endocrinology and Diabetes, Phoenix Children's Hospital, Phoenix, Arizona.

Elva Hooker (E)

Ivy Center for Family Wellness, The Society of St Vincent de Paul, Phoenix, Arizona.

Stephanie L Ayers (SL)

Southwest Interdisciplinary Research Center, Arizona State University, Phoenix.

Felipe González Castro (FG)

Center for Health Promotion and Disease Prevention, Arizona State University, Phoenix.

Donald L Patrick (DL)

School of Public Health, University of Washington, Seattle.

Libby Corral (L)

Valley of the Sun YMCA, Phoenix, Arizona.

Elvia Lish (E)

Ivy Center for Family Wellness, The Society of St Vincent de Paul, Phoenix, Arizona.

William C Knowler (WC)

National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona.

Gabriel Q Shaibi (GQ)

Center for Health Promotion and Disease Prevention, Arizona State University, Phoenix.
Division of Pediatric Endocrinology and Diabetes, Phoenix Children's Hospital, Phoenix, Arizona.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH